Linking Real-world Mobility to Molecular Markers of Neuroaxonal Damage in People With Progressive Multiple Sclerosis
Ahmed Abdelhak1, Gabby Joseph2, Riley Bove3, Bruce Cree5, Valerie Block4
1Neurology, UCSF Weill Institute of Neuroscience, 2Radiology and Biomedical Imaging, UCSF, 3University of California, San Francisco, 4Weill, Neurology, University of California, San Francisco, 5UCSF, Multiple Sclerosis Center
Objective:

Assess associations between serum neurofilament light chain (sNfL) levels and step count in a large international cohort of people with progressive multiple sclerosis (MS) who participated in a randomized controlled trial.

Background:
sNfL is a sensitive biomarker of neuroaxonal injury in MS, yet associations with real-world functional outcomes remain poorly characterized. Daily step count from remote wearables devices provides an ecologically-valid measure of ambulatory function that captures home-based mobility patterns missed by episodic assessments.
Design/Methods:

A post-hoc analysis of SPI2 (high-dose biotin [MD1003] vs. placebo) was conducted. The two treatment arms were analyzed together because no therapeutic benefit of MD1003 was observed. Participants with paired sNfL (z-scores) and step count data were included. Daily steps were averaged within ±15-day windows around each timepoint. The associations between sNfL z-scores and step count were assessed using bootstrapped (1000x) mixed-effects negative binomial regression models (accounting for multiple measurements/person), adjusting for age and sex.

Results:

630 participants contributed 1,985 observations over 15 months. 54% were female, mean 52.7 [SD 7.7] years old, median Expanded Disability Status Scale (EDSS) score: 6 [IQR 4.5-6], and mean sNfL of 15.2 pg/mL (SD: 9.6). The median daily steps were 3,047 (IQR: 1,621–4,982). 10% exceeded 7,200 steps/day, consistent with prior cohorts with comparable disability. Fewer daily steps were significantly associated with higher sNfL: each one-unit sNfL increase corresponded to 3.4% fewer steps (IRR=0.97, 95% CI 0.94–0.99 p=0.014). This association was not impacted by EDSS category (≥5.0 or <5.0) or treatment group (MD1003 or placebo) on the steps outcome (p>0.05).

Conclusions:

Reduced ambulatory activity was associated with elevated sNfL levels, linking real-world mobility to molecular markers of neuroaxonal damage. Both measures appeared more sensitive than EDSS in capturing subtle changes in disease status. Results support the integration of fluid and digital biomarkers to enhance sensitivity for detecting progression in clinical trials and routine practice.

 

10.1212/WNL.0000000000215197
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.